Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

ABSTRACT: The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may increase efficacy for patients with metastatic colorectal cancer who progressed on prior chemotherapy. This approach is biologically directed to overall target the cancer cell at multiple levels, and potentially preventing chemotherapy and EGFR-therapy resistance.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2043695 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR